Entity

Time filter

Source Type

Minneapolis, MN, United States

Medtronic plc has its principal offices in Ireland, its operational headquarters in suburban Minneapolis, Minnesota and is the world's third largest medical device company. In 2015, at the time of its relocation, Medtronic had the largest market capitalization of any company in Ireland: its market cap was about $100 billion while the market cap for CRH, Ireland’s largest indigenous business, was $18.4 billion.Medtronic operates in more than 160 countries. The company employs 85,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents. Wikipedia.


Glotzer T.V.,Hackensack University Medical Center | Ziegler P.D.,Medtronic Inc.
Canadian Journal of Cardiology | Year: 2013

The term "silent" atrial fibrillation (AF) has recently re-emerged to describe atrial arrhythmias that are detected by implanted cardiac devices but would generally go undetected in the clinical setting. The precise role that silent AF plays in increasing the risk of ischemic stroke is not fully understood. The purpose of this article is to: (1) review the current evidence demonstrating that silent AF is associated with thromboembolic events; (2) describe the temporal proximity of silent AF episodes to thromboembolic events; (3) present data on the incidence of newly detected silent AF in patients without a previous history of AF; and (4) provide an overview of ongoing and new clinical studies on this important topic. The current evidence suggests that the prevalence of silent AF is considerable among patients with implanted devices, and that the presence of silent AF increases the risk of thromboembolism. The AF burden threshold which confers this increased thromboembolism risk is not precisely defined, but might be as brief as several minutes to several hours. The advent of novel oral anticoagulation medications, which offer the promise of improved efficacy along with superior safety profiles, might warrant more aggressive identification of patients who might benefit from these therapies. However, to find high risk patients who have brief episodes of silent AF will likely require new methods of monitoring to permit the detection of this elusive but potentially dangerous arrhythmia. © 2013 Canadian Cardiovascular Society. Source


Mcelhinney D.B.,NYU Langone Medical Center | Hennesen J.T.,Medtronic Inc.
Annals of the New York Academy of Sciences | Year: 2013

The Melody® transcatheter pulmonary valve (TPV) is a percutaneous valve system designed for the treatment of obstruction and/or regurgitation of prosthetic conduits placed between the right ventricle and pulmonary arteries in patients with congenital heart disease. In 2000, Melody TPV became the first transcatheter valve implanted in a human; in 2006 it became the first transcatheter valve commercially available anywhere in the world; and in 2010 it was launched as the first commercially available transcatheter valve in the United States. In this review, we present the clinical background against which the Melody valve was developed and implemented, introduce the rationale for and challenges of transcatheter valve technology for this population, outline the history and technical details of its development and use, and summarize currently available data concerning the performance of the device. © 2013 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences. Source


Glotzer T.V.,Hackensack University Medical Center | Ziegler P.D.,Medtronic Inc.
Heart Rhythm | Year: 2015

BACKGROUND: Stroke without an identifi able cause is frightening to patients and their families and is frustrating for the caring physician. Approximately 30% of patients with cardiac implanted electronic devices have some evidence of atrial fi brillation (AF), and much of it is silent: asymptomatic, and previously unrecognized. OBJECTIVE: The purpose of this review is to examine "silent AF" as a potential cause of cryptogenic stroke. METHODS/RESULTS: We begin by reviewing most of the published literature on screening for AF with different monitoring technologies in the setting of cryptogenic stroke. We present the results of 2 recent large randomized trials, CRYSTAL AF and EMBRACE, which compare standard of care monitoring in cryptogenic stroke patients to invasive and noninvasive monitoring strategies, respectively. Finally, we review the relationship of silent AF to stroke in the cardiac implanted electronic device population. Patient selection, duration of monitoring, sensitivity and speci fi city of monitoring technology, patient compliance, and several other factors affect the yield of AF detection during monitoring. CONCLUSION: Data suggest that silent AF is identifi ed in approximately 30% of cryptogenic stroke patients and has important therapeutic implications. Oral anticoagulation likely should be prescribed when silent AF is detected. © 2015 Heart Rhythm Society. All rights reserved. Source


Patent
Medtronic Inc. | Date: 2013-03-06

A trial stimulation system includes a disposable trial electrical stimulator that, in some examples, is sterilized for a single use in a stimulation trial of one patient. Additionally, systems for securing a disposable trial stimulator to the body of a patient are described, which may function to improve the durability of the system during the trial period and reduce the risk of damage or malfunction to the system due to lead/electrode dislocation and/or off-label uses like showering or bathing with the trial stimulator still secured to the body.


Patent
Medtronic Inc. | Date: 2014-06-02

A medical device and medical method. The medical device includes a flexible elongate body defining a proximal end and a distal end. The elongate body defines a first lumen spanning from the proximal end to a location proximal to the distal end. A shaping member insertable within the first lumen is included, the shaping member is configured to retain a manipulated shape when the flexible elongate body is manipulated from a first configuration to a second configuration. A tip is coupled to the distal end.

Discover hidden collaborations